2seventy bio, Inc.

NasdaqGS:TSVT Stock Report

Market Cap: US$266.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

2seventy bio Management

Management criteria checks 0/4

2seventy bio's CEO is Chip Baird, appointed in Apr 2024, has a tenure of 1.08 years. total yearly compensation is $5.04M, comprised of 11.2% salary and 88.8% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $591.04K. The average tenure of the management team and the board of directors is 1.1 years and 2.9 years respectively.

Key information

Chip Baird

Chief executive officer

US$5.0m

Total compensation

CEO salary percentage11.21%
CEO tenure1.1yrs
CEO ownership0.2%
Management average tenure1.1yrs
Board average tenure2.9yrs

Recent management updates

Recent updates

Seeking Alpha • Mar 12

Bristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy Pioneer

Summary It was revealed Monday that Pharma giant Bristol-Myers Squibb will acquire all outstanding shares of 2seventy bio for $5, valuing the deal at ~$286m. 2seventy bio, a Cambridge-based biotech formerly part of bluebird bio, helped develop the first FDA-approved CAR T cell therapy for multiple myeloma, Abecma. Abecma was once considered a $1bn per annum revenue drug, but rival Carvykti is winning the battle for market share and $500m revenues p.a. is a more realistic target. 2seventy had sold off all of its other programs and halted a study of Abecma as a first line therapy - a disappointing end to a once-promising company. Bluebird Bio was also recently acquired for just $29m, albeit with CVRs attached to the deal. It seems a shame 2seventy did not try to negotiate something similar. Read the full article on Seeking Alpha
Analysis Article • Dec 31

2seventy bio, Inc.'s (NASDAQ:TSVT) 28% Dip In Price Shows Sentiment Is Matching Revenues

Unfortunately for some shareholders, the 2seventy bio, Inc. ( NASDAQ:TSVT ) share price has dived 28% in the last...
Seeking Alpha • Dec 23

2seventy bio: All In On Abecma Multiple Myeloma Treatment

Summary 2seventy bio, spun off from bluebird bio in 11/2021, now has a three-year track record as an independent company in cell therapies. Small biotechs like 2seventy bio face significant challenges in the competitive and demanding field of cell therapies. The article evaluates 2seventy bio's investment prospects, considering its performance and strategic positioning since the spin-off. The analysis aims to determine if 2seventy bio is a better investment bet in the cell therapy sector compared to its peers. Read the full article on Seeking Alpha
Analysis Article • Nov 15

Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report

There's been a major selloff in 2seventy bio, Inc. ( NASDAQ:TSVT ) shares in the week since it released its quarterly...
Analysis Article • Oct 03

There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

You may think that with a price-to-sales (or "P/S") ratio of 5.6x 2seventy bio, Inc. ( NASDAQ:TSVT ) is definitely a...
Analysis Article • Jul 04

2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

With a price-to-sales (or "P/S") ratio of 2.9x 2seventy bio, Inc. ( NASDAQ:TSVT ) may be sending very bullish signals...
Analysis Article • May 11

Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

One thing we could say about the analysts on 2seventy bio, Inc. ( NASDAQ:TSVT ) - they aren't optimistic, having just...
Seeking Alpha • Apr 03

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Summary 2seventy bio is focusing on ABECMA, their CAR-T cell therapy for multiple myeloma, and expects label expansion approval. ABECMA has shown positive real-world evidence and has the potential for significant market growth. The company's financial position is strong, with a cash runway past 2027, and they anticipate a return to growth if the label expansion is approved. Read the full article on Seeking Alpha
Analysis Article • Mar 07

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

Today is shaping up negative for 2seventy bio, Inc. ( NASDAQ:TSVT ) shareholders, with the analysts delivering a...
Analysis Article • Feb 06

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Despite an already strong run, 2seventy bio, Inc. ( NASDAQ:TSVT ) shares have been powering on, with a gain of 49% in...
Analysis Article • Jan 17

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Dec 13

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Those holding 2seventy bio, Inc. ( NASDAQ:TSVT ) shares would be relieved that the share price has rebounded 44% in the...
Analysis Article • May 05

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

Celebrations may be in order for 2seventy bio, Inc. ( NASDAQ:TSVT ) shareholders, with the analysts delivering a...
Analysis Article • Mar 21

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

2seventy bio, Inc. ( NASDAQ:TSVT ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article • Mar 19

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

2seventy bio, Inc. ( NASDAQ:TSVT ) investors will be delighted, with the company turning in some strong numbers with...

CEO Compensation Analysis

How has Chip Baird's remuneration changed compared to 2seventy bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$4m

Dec 31 2024US$5mUS$564k

-US$57m

Sep 30 2024n/an/a

-US$95m

Jun 30 2024n/an/a

-US$156m

Mar 31 2024n/an/a

-US$223m

Dec 31 2023US$3mUS$518k

-US$218m

Sep 30 2023n/an/a

-US$184m

Jun 30 2023n/an/a

-US$180m

Mar 31 2023n/an/a

-US$215m

Dec 31 2022n/an/a

-US$254m

Sep 30 2022n/an/a

-US$292m

Jun 30 2022n/an/a

-US$284m

Mar 31 2022n/an/a

-US$291m

Dec 31 2021US$2mUS$491k

-US$292m

Sep 30 2021n/an/a

-US$308m

Jun 30 2021n/an/a

-US$320m

Mar 31 2021n/an/a

-US$222m

Dec 31 2020US$2mUS$475k

-US$120m

Compensation vs Market: Chip's total compensation ($USD5.04M) is above average for companies of similar size in the US market ($USD1.60M).

Compensation vs Earnings: Chip's compensation has increased whilst the company is unprofitable.

CEO

Chip Baird (52 yo)

1.1yrs
Tenure
US$5,036,036
Compensation

Mr. William D. Baird III, also known as Chip, serves as Chief Executive Officer, President and Director of 2seventy bio, Inc. since April 1, 2024. He was Principal Financial Officer and Principal Accountin...

Leadership Team

NamePositionTenureCompensationOwnership
William Baird
CEO, President & Director1.1yrsUS$5.04m0.22%
$ 591.0k
Victoria Eatwell
Chief Financial Officer1.1yrsUS$2.35m0.83%
$ 2.2m
Jessica Snow
Chief Operating Officer1.1yrsUS$1.53m0.48%
$ 1.3m
1.1yrs
Average Tenure
45yo
Average Age

Experienced Management: TSVT's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
William Baird
CEO, President & Director1.1yrsUS$5.04m0.22%
$ 591.0k
Eli Casdin
Independent Director1.2yrsUS$279.10kno data
Nick Leschly
Chairman of the Board4yrsUS$9.76m2.42%
$ 6.4m
Charles Newton
Independent Director1.2yrsUS$289.85kno data
Marcela Maus
Independent Director3.6yrsUS$165.83k0.022%
$ 58.5k
Denice Torres
Lead Independent Director3.6yrsUS$214.20k0.037%
$ 97.5k
Sarah J. Glickman
Independent Director3.6yrsUS$189.45k0.027%
$ 73.0k
Wei Lin
Independent Director2.2yrsUS$167.70k0.018%
$ 48.7k
2.9yrs
Average Tenure
53yo
Average Age

Experienced Board: TSVT's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/15 21:38
End of Day Share Price 2025/05/12 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

2seventy bio, Inc. is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Salveen RichterGoldman Sachs